Evolus, Inc. raised earnings guidance for the full year 2023. For the year, the company now expects total net revenues to be between $194 million and $198 million from $185 Million to $195 Million, representing year-over-year growth of greater than 30% and magnitudes above the estimated growth rate of the aesthetic neurotoxin market.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.88 USD | -1.00% | +1.98% | +22.32% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.32% | 815M | |
+42.83% | 748B | |
+34.11% | 598B | |
-5.70% | 356B | |
+18.06% | 325B | |
+4.63% | 283B | |
+17.02% | 245B | |
+9.26% | 211B | |
-4.21% | 209B | |
+2.43% | 166B |
- Stock Market
- Equities
- EOLS Stock
- News Evolus, Inc.
- Evolus, Inc. Raises Earnings Guidance for the Full Year 2023